Everolimus for the treatment of pancreatic neuroendocrine tumors

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 14, 2012, Pages 2073-2084

  Feldmann, Georg ^a   Bisht, Savita ^a   Schütte, Ute ^a   Haarmann, Jens ^a   Brossart, Peter ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Everolimus; MTOR signaling; Pancreatic cancer; Pancreatic neuroendocrine tumors; Rapamycin; Targeted therapy

Indexed keywords

ANGIOPEPTIN; EVEROLIMUS; OCTREOTIDE;

APHTHOUS ULCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CLINICAL FEATURE; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOPHOSPHATEMIA; LEUKOPENIA; MOLECULAR GENETICS; PANCREATIC NEUROENDOCRINE TUMOR; PATHOPHYSIOLOGY; PNEUMONIA; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84866248820     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.713348     Document Type: Article

References (106)

1. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135(5):1469-92
2. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26(18):3063-72
3. de Wilde RF, Edil BH, Hruban RH, et al. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol 2012;9(4):199-208
4. Halfdanarson TR, Rabe KG, Rubin J, et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;19(10):1727-33
5. Liakakos T, Roukos DH. Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors. Future Oncol 2011;7(9):1025-9
6. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12(4):1083-92 (Pubitemid 41815799)
7. Fendrich V, Bartsch DK. Surgical treatment of gastrointestinal neuroendocrine tumors. Langenbecks Arch Surg 2011;396(3):299-311
8. Fischer L, Mehrabi A, Buchler MW. Neuroendocrine tumors of the duodenum and pancreas. Surgical strategy. Chirurg 2011;82(7):583-90
9. Vavra JJ, Deboer C, Dietz A, et al. Streptozotocin, a new antibacterial antibiotic. Antibiot Annu 1959;7:230-5
10. Herr RR, Eble TE, Bergy ME, et al. Isolation and characterization of streptozotocin. Antibiot Annu 1959;7:236-40
11. Sokolski WT, Vavra JJ, Hanka LJ. Assay methods and antibacterial studies on streptozotocin. Antibiot Annu 1959;7:241-6
12. Lewis C, Barbiers AR. Streptozotocin, a new antibiotic. In vitro and in vivo evaluation. Antibiot Annu 1959;7:247-54
13. Hanka LJ, Sokolski WT. Bacterial resistance to streptozotocin. Antibiot Annu 1959;7:255-61
14. Rakieten N, Rakieten ML, Nadkarni MR. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 1963;29:91-8
15. Evans JS, Gerritsen GC, Mann KM, et al. Antitumor and hyperglycemic activity of streptozotocin (NSC-37917) and its cofactor, U-15,774. Cancer Chemother Rep 1965;48:1-6
16. Mansford KR, Opie L. Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. Lancet 1968;1(7544):670-1
17. Murray-Lyon IM, Eddleston AL, Williams R, et al. Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet 1968;2(7574):895-8
18. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980;303(21):1189-94 (Pubitemid 11207582)
19. Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973;79(1):108-18
20. Chernicoff D, Bukowski RM, Groppe CW Jr, et al. Combination chemotherapy for islet cell carcinoma and metastatic carcinoid tumors with 5-fluorouracil and streptozotocin. Cancer Treat Rep 1979;63(5):795-6 (Pubitemid 9248175)
21. Oberstein PE, Remotti H, Saif MW, et al. Pancreatic neuroendocrine tumors: entering a new era. JOP 2012;13(2):169-73
22. Turner NC, Strauss SJ, Sarker D, et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010;102(7):1106-12
23. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326(8):519-23
24. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999;86(6):944-8 (Pubitemid 29439847)
25. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22(23):4762-71
26. McCollum AD, Kulke MH, Ryan DP, et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 2004;27(5):485-8 (Pubitemid 39371944)
27. Eriksson B, Skogseid B, Lundqvist G, et al. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990;65(9):1883-90 (Pubitemid 20147622)
28. Gibson NW, Erickson LC, Hickman JA. Effects of the antitumor agent 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one on the DNA of mouse L1210 cells. Cancer Res 1984;44(5):1767-71 (Pubitemid 14145711)
29. Gibson NW, Hickman JA, Erickson LC. DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2- chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one. Cancer Res 1984;44:5.1772-5
30. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res 2006;12(2):328-31 (Pubitemid 43166117)
31. Bracht LK, Wen P, Meyerhardt JA, et al. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. J Clin Oncol 2008;26(29):4843-4
32. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009;15(1):338-45
33. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13(10):2986-91 (Pubitemid 46849574)
34. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24(3):401-6 (Pubitemid 46630459)
35. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117(2):268-75
36. Walter T, Bruneton D, Cassier PA, et al. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors. Clin Colorectal Cancer 2010;9(4):248-54
37. de Mestier L, Hammel P, Hentic O, et al. Dramatic efficacy of chemotherapy with 5-fluorouracil and dacarbazine in a patient with metastatic glucagonoma and cardiac insufficiency. Gastroenterol Clin Biol 2010;34(1):106-10
38. Ramanathan RK, Cnaan A, Hahn RG, et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001;12(8):1139-43
39. Ohshio G, Hosotani R, Imamura M, et al. Gastrinoma with multiple liver metastases: effectiveness of dacarbazine (DTIC) therapy. J Hepatobiliary Pancreat Surg 1998;5(3):339-43 (Pubitemid 128662603)
40. Bajetta E, Rimassa L, Carnaghi C, et al. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 1998;83(2):372-8 (Pubitemid 28317819)
41. Kurose T, Seino Y, Ishida H, et al. Successful treatment of metastatic glucagonoma with dacarbazine. Lancet 1984;1(8377):621-2 (Pubitemid 14156526)
42. Furstenberger G, Schmid P, Duquesne A, et al. Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy. Cancer Chemother Pharmacol 2008;61(2):347-8 (Pubitemid 350160332)
43. Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007;59(5):637-42 (Pubitemid 46295128)
44. Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Contr 2011;18(2):127-37
45. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999;340(11):858-68 (Pubitemid 29142631)
46. Arnaldi G, Boscaro M. Pasireotide for the treatment of Cushing's disease. Expert Opin Investig Drugs 2010;19(7):889-98
47. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 2009;27(28):4656-63
48. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331(6021):1199-203
49. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321(5897):1801-6
50. Corbo V, Dalai I, Scardoni M, et al. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer 2010;17(3):771-83
51. Toliat MR, Berger W, Ropers HH, et al. Mutations in the MEN I gene in sporadic neuroendocrine tumours of gastroenteropancreatic system. Lancet 1997;350(9086):1223 (Pubitemid 127445099)
52. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276(5311):404-7
53. Bassett JH, Forbes SA, Pannett AA, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 1998;62(2):232-44 (Pubitemid 28110764)
54. Agarwal SK, Lee Burns A, Sukhodolets KE, et al. Molecular pathology of the MEN1 gene. Ann NY Acad Sci 2004;1014:189-98 (Pubitemid 38594805)
55. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): Analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008;29(1):22-32
56. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86(12):5658-71 (Pubitemid 33152604)
57. Wu X, Hua X. Menin, histone h3 methyltransferases, and regulation of cell proliferation: current knowledge and perspective. Curr Mol Med 2008;8(8):805-15
58. Thomas-Marques L, Murat A, Delemer B, et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 2006;101(2):266-73 (Pubitemid 43381666)
59. Triponez F, Dosseh D, Goudet P, et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 2006;243(2):265-72 (Pubitemid 43185447)
60. Kouvaraki MA, Shapiro SE, Cote GJ, et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 2006;30(5):643-53 (Pubitemid 43724089)
61. Wamsteker EJ, Gauger PG, Thompson NW, et al. EUS detection of pancreatic endocrine tumors in asymptomatic patients with type 1 multiple endocrine neoplasia. Gastrointest Endosc 2003;58(4):531-5 (Pubitemid 37205765)
62. Pipeleers-Marichal M, Somers G, Willems G, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med 1990;322(11):723-7 (Pubitemid 20092807)
63. Elsasser SJ, Allis CD, Lewis PW. Cancer. New epigenetic drivers of cancers. Science 2011;331(6021):1145-6
64. Drane P, Ouararhni K, Depaux A, et al. The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev 2010;24(12):1253-65
65. Goldberg AD, Banaszynski LA, Noh KM, et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 2010;140(5):678-91
66. Wong LH, McGhie JD, Sim M, et al. ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Res 2010;20(3):351-60
67. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011;333(6041):425
68. Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010;28(2):245-55
69. Kasajima A, Pavel M, Darb-Esfahani S, et al. MTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2011;18(1):181-92
70. Shida T, Kishimoto T, Furuya M, et al. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother Pharmacol 2010;65(5):889-93
71. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8(3):179-83 (Pubitemid 41317589)
72. Speel EJ, Richter J, Moch H, et al. Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol 1999;155(6):1787-94
73. Perren A, Komminoth P, Saremaslani P, et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 2000;157(4):1097-103
74. Benjamin D, Colombi M, Moroni C, et al. Rapamycin passes the torch: A new generation of mTOR inhibitors. Nat Rev Drug Discov 2011;10(11):868-80
75. Populo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci 2012;13(2):1886-918
76. Albert S, Serova M, Dreyer C, et al. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs 2010;19(8):919-30
77. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011;121(4):1231-41
78. Willems L, Tamburini J, Chapuis N, et al. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 2012;14(2):129-38
79. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):514-23
80. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28(10):721-6
81. Miller JL. Sirolimus approved with renal transplant indication. Am J Health Syst Pharm 1999;56(21):2177-8
82. Phung TL, Ziv K, Dabydeen D, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006;10(2):159-70 (Pubitemid 44175906)
83. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12(1):122-7 (Pubitemid 43050086)
84. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006;25(2):420-8 (Pubitemid 43529550)
85. Gabardi S, Baroletti SA. Everolimus: A proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 2010;30(10):1044-56
86. Sedrani R, Cottens S, Kallen J, et al. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc 1998;30(5):2192-4 (Pubitemid 28399473)
87. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43(2):83-95 (Pubitemid 38283132)
88. Segarra I, Brazelton TR, Guterman N, et al. Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin. J Chromatogr B Biomed Sci Appl 1998;720(1-2):179-87 (Pubitemid 29000945)
89. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64(1):36-42 (Pubitemid 27327197)
90. Dumont FJ. Everolimus novartis. Curr Opin Investig Drugs 2001;2(9):1220-34
91. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22(2):159-68
92. Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of rifampin on apparent clearance of everolimus. Ann Pharmacother 2002;36(6):981-5 (Pubitemid 34564379)
93. Zitzmann K, De Toni EN, Brand S, et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007;85(1):54-60 (Pubitemid 46550026)
94. Tuveson D, Hanahan D. Translational medicine: cancer lessons from mice to humans. Nature 2011;471(7338):316-17
95. Chiu CW, Nozawa H, Hanahan D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol 2010;28(29):4425-33
96. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26(26):4311-18.
97. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol 2010;28(1):69-76.
98. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65
99. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363(19):1801-11
100. Drugs-U.S. Food and Drug Administration. Available from: http://www.fda.gov/Drugs/default.htm
101. Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) (EXIST-2). Available from: http://clinicaltrials.gov/ct2/show/NCT00790400? term=NCT00790400&rank=1
102. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):501-13.
103. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009;361(12):1173-8
104. Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res 2007;67(5):2187-96 (Pubitemid 46424238)
105. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324(5933):1457-61
106. Cook N, Frese KK, Bapiro TE, et al. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med 2012;209(3):437-44